Drug class
Phosphatidylinositol-3-kinase (PI3K) inhibitor; targeted antineoplastic kinase inhibitor (withdrawn US indication)
Mechanism of action
Inhibits class I PI3K isoforms, with activity against PI3K-alpha and PI3K-delta, reducing downstream AKT signalling involved in tumour-cell proliferation and survival.
General use cases
- Historical US indication: treatment of adults with relapsed follicular lymphoma after at least two systemic therapies. The US approval for ALIQOPA was withdrawn in 2023 following voluntary withdrawal; do not present this as a current US-authorised treatment.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
